Early changes in 18F-FDG PET following nivolumab (nivo), and ipilimumab- nivolumab (ipi nivo) and predicting outcome in patients with metastatic renal cancer

When advanced kidney cancer spreads to other parts of the body, doctors often turn to a powerful type of treatment called immunotherapy. Instead of attacking the cancer directly with poison or radiation, this approach wakes up the patient's own immune system, training it to recognize and destroy the rogue cells. However, a major challenge remains: there is no reliable way to know quickly if this treatment is working. Standard scans look at the size of tumors, but immune cells can cause swelling and inflammation that makes a tumor look bigger before it actually shrinks. This creates a confusing picture where a patient might be getting better while the images suggest they are getting worse. Scientists have long wondered if they could spot these early signs of the immune system fighting back, perhaps by seeing a temporary surge in activity that signals the treatment is taking hold.

A team of researchers at Lancashire Teaching Hospitals in the United Kingdom set out to investigate this possibility using a special kind of camera called a PET scanner. This machine detects a radioactive sugar that healthy cells and cancer cells both eat, but cancer cells usually eat much more of it. When the scanner lights up, it shows where the cells are most active. The researchers focused on patients with metastatic kidney cancer, meaning the disease had spread from the kidney to other organs. They wanted to see what happened just two weeks after patients started receiving immunotherapy. The idea was that if the immune system was successfully attacking the cancer, it might rush into the tumors, causing a temporary spike in activity that the scanner could catch. This phenomenon, known as a "flare," could serve as an early warning sign that the treatment is effective, allowing doctors to avoid continuing useless therapies that only cause side effects.

The study involved thirty patients who were about to begin treatment. Ten of them received a combination of two immunotherapy drugs as their first line of defense, while the other twenty received a single drug as a second-line treatment after other options had failed. Before starting the medication, each patient underwent a PET scan to establish a baseline. Two weeks later, after receiving their first doses, they returned for another scan. The researchers carefully measured the activity levels in the tumors, looking for any changes that occurred in such a short time. They found that the tumors were not uniform; within a single patient, different spots of cancer showed different levels of activity. This made the task of tracking changes complex, as the researchers had to compare specific spots before and after treatment.

The results revealed a fascinating pattern. In many patients, the tumors did not shrink immediately; instead, they became more active. For those on the single drug, eight out of fifteen patients showed a significant increase in activity in their tumors just two weeks into treatment. For those on the combination therapy, five out of nine patients showed a similar surge. This increase, or flare, happened because the immune cells were flooding the tumor site and consuming the radioactive sugar, lighting up the scan. The researchers observed that this flare was not random; it tended to happen in patients who would eventually have a good response to the treatment. Among the patients whose tumors eventually stopped growing or shrank, the majority had experienced this early spike in activity. In fact, the two patients who achieved a complete disappearance of their cancer had very large flares, with activity levels jumping by more than fifty percent.

Despite these encouraging signs, the study also highlighted the limits of what can be concluded from such a small group. While there was a clear trend suggesting that a bigger flare often meant a better outcome, the numbers were not large enough to prove this relationship with absolute certainty. The researchers found that the size of the tumor before treatment started did not predict who would respond to the drugs. Furthermore, when they looked at patients whose tumors got smaller, they did not see a consistent pattern that would allow them to use a decrease in activity as a reliable early sign of success. The data suggested that a temporary increase in activity is a more promising indicator than a decrease, but the evidence remains suggestive rather than definitive.

The study also uncovered something unexpected about the side effects of this treatment. In two patients, the immune system became so active that it attacked normal, healthy tissue. One patient developed an overactive thyroid gland, and another had a reaction in the lymph nodes of the chest. These events also showed up as flares on the PET scans, raising the possibility that this same imaging technique could one day help doctors spot dangerous side effects before they become severe. The researchers noted that while their findings are the first to show this specific type of flare in kidney cancer patients, the study was too small to change medical practice immediately. They emphasized that larger studies are needed to confirm whether this early surge in activity can reliably guide treatment decisions. For now, the work offers a glimpse into the complex, dynamic battle between the immune system and cancer, showing that sometimes, the first sign of victory looks like a temporary intensification of the fight.